Lupin Ltd Share Price

Overview

Lupin Ltd share price is currently ₹2,176.95, up by ₹11.04 (0.51%) from its previous closing price of ₹2,165.91. The share price has declined -8.43% over the past month and gained 9.97% over the past year. The stock's 52-week low and high are ₹1,851.96 and ₹2,505.27, respectively. Lupin Ltd has a market capitalisation of ₹ 1,00,000.00 Cr. The share price was last updated on 21 Aug 2026, 03:51 PM IST.

Lupin Ltd

LUPIN

₹0.00

₹11.04

0.51%

Healthcare

₹0.00(%)1D

Updated: 21 Aug 2026, 03:51:59 pm IST

Market Data

Open Price

₹2,175.96

Prev. Close

₹2,165.91

₹2,161.95

Day Low

₹2,191.68

Day High

₹1,851.96

52 Week Low

₹2,505.27

52 Week High

HealthcarePharmaceuticals & Drugs

CategoryLarge Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

18.00

Sector PE

42.16

PB Ratio

4.45

Sector PB

5.82

EPS

120.97

Dividend Yield

0.78

Today's Volume

767.915 K

5 Day Avg. Volume

698.826 K

PEG Ratio

0.29

Market Cap.

₹ 1,00,000.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 900% at ₹18/Share	17-Jul-2026	17-Jul-2026
DividendsFinal Dividend of 600% at ₹12/Share	25-Jul-2025	25-Jul-2025

Mutual Fund Ownership

Mutual Fund Holder	Jun 26 Shares held	Jul 26 Shares held
HDFC Balanced Advantage Fund - Growth	56.86 Lac	56.86 Lac no change
HDFC Large Cap Fund - Growth	46.16 Lac	46.16 Lac no change
HDFC Flexi Cap Fund - Growth	36.87 Lac	44.16 Lac (19.76%)
Mirae Asset Large & Midcap Fund - Regular Plan - Growth	36.89 Lac	36.89 Lac no change
Nippon India Pharma Fund - Growth	27.84 Lac	27.84 Lac no change

Show all holdings

About Lupin Ltd 👋

Lupin Limited is a pharmaceutical company, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It operates in India and the United States across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. It has presence in the Cardiovascular, Diabetology, Asthama, Pediatrics, Central Nervous System, GastroIntestinal, Anti-Infectives and Nonsteroidal Anti-Inflammatory Drug therapy segments and operates in the Anti-TB and Cephalosporins segments. Its ophthalmology portfolio includes over 60 branded products spanning dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialty nutraceuticals across European markets. Its diabetes brands include GIBTULIO, AJADUO, GIBTULIO MET, ONDERO, ONDERO MET, and Huminsulin.